NASDAQ:IMVT Immunovant Q4 2025 Earnings Report $33.30 -0.70 (-2.06%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$33.10 -0.20 (-0.60%) As of 09/25/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immunovant EPS ResultsActual EPS-$0.64Consensus EPS -$0.72Beat/MissBeat by +$0.08One Year Ago EPS-$0.52Immunovant Revenue ResultsActual Revenue$0.16 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmunovant Announcement DetailsQuarterQ4 2025Date5/29/2025TimeBefore Market OpensConference Call DateThursday, May 29, 2025Conference Call Time7:00AM ETUpcoming EarningsImmunovant's Q2 2027 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Immunovant Earnings HeadlinesImmunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)September 25 at 2:00 PM | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS)September 24 at 10:27 PM | theglobeandmail.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.September 27 at 1:00 AM | Stansberry Research (Ad)Roivant reports top-line data from IMVT-1402 CLE trialSeptember 24 at 7:26 AM | finance.yahoo.comImmunovant Proof-of-Trial for IMCT-1402 Misses Primary EndpointSeptember 23, 2026 | marketwatch.comImmunovant stock slides after biotech scraps autoimmune drug programSeptember 23, 2026 | msn.comSee More Immunovant Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunovant? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your email. Email Address About ImmunovantImmunovant (NASDAQ:IMVT) (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company developing therapies for patients with immune-mediated diseases. The company focuses on conditions in which disease-causing antibodies, or immunoglobulin G (IgG), play a central role, including autoimmune and inflammatory disorders. Immunovant’s lead product candidate is batoclimab, an investigational fully human monoclonal antibody designed to block the neonatal Fc receptor (FcRn). By inhibiting FcRn, batoclimab is intended to reduce circulating IgG antibodies that can contribute to autoimmune disease. The company has evaluated the therapy in conditions including thyroid eye disease, myasthenia gravis and Graves’ disease. Immunovant is also advancing IMVT-1402, an investigational next-generation FcRn inhibitor intended to support the treatment of autoimmune disorders. Immunovant was established as a subsidiary of Roivant Sciences and operates as part of Roivant’s broader biotechnology platform. Its programs are being developed for potential use in the United States and other international markets through clinical research and regulatory activities. The company is led by Chief Executive Officer Pete Salzmann, M.D., and is headquartered in New York.View Immunovant ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
